Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combi-TED: Tedopi plus docetaxel or nivolumab vs docetaxel in second-line metastatic NSCLC after chemo-immunotherapy
2020-005170-10Phase 2Terminated
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tedopi + docetaxel, Tedopi + nivolumab and Docetaxel monotherapy (3 arms). Primary endpoint: 1-year Survival Rate. Started Jun 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-005170-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005170-10.